Anti-C5 Polyclonal Antibody from ProteoGenix; catalogue PTX19487; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-C5 Polyclonal Antibody is a ProteoGenix primary antibody supplied under catalogue number PTX19487 for research use only.
Target: Human; Host: Rabbit; Clonality: Polyclonal Antibody; Applications: IHC, ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
C5 (complement C5) is a complement-system precursor cleaved into C5a and C5b, coupling complement activation to inflammatory signalling and membrane attack complex assembly.
Biological function: C5 convertases cleave complement C5 to generate C5a and C5b. C5a is a potent anaphylatoxin and chemoattractant that drives inflammatory leukocyte responses, whereas C5b initiates assembly of the terminal complement complex with C6-C9, leading to membrane attack complex formation.
